NexPlasmaGen wins a Corporate Livewire Innovation & Excellence Award | NexPlasmaGen
17258
post-template-default,single,single-post,postid-17258,single-format-standard,bridge-core-2.6.4,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-theme-ver-24.9,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,qode-wpml-enabled,wpb-js-composer js-comp-ver-7.7,vc_responsive

NexPlasmaGen wins a Corporate Livewire Innovation & Excellence Award

NexPlasmaGen wins a Corporate Livewire Innovation & Excellence Award

Montreal / September 19, 2024 – NexPlasmaGen wins the Corporate Livewire magazine’s Innovation and Excellence Award – Cancer Treatment Technology Company of 2024

The Corporate LiveWire Innovation & Excellence Awards celebrate the success and achievements of leading professionals and companies who have stood out for being results driven, service focused and most importantly, taken an innovative approach to demonstrate exceptional business performance. Over the past year 9,246 nominations were received by the awards team at Corporate LiveWire from 19 countries around the world. Winners were chosen for industry recognition, innovative use of technology in research and development, branding, and most importantly service excellence.

Awards Judge, Andrew White commented: “It was a difficult task to pick the winners with fierce competition in this year’s award. Each winner has made a substantial contribution to their sector with an innovative view to pushing business success and ideas. We are keen to see how they will continue to demonstrate their commitment in the future.” (Corporate Livewire Innovation Awards)

“This prestigious award is another fine recognition of the tireless work of our small startup NexPlasmaGen. We extend this recognition for the progress of our technology to treat cancer to our close collaborators CHUM, McGill University, Université de Montréal and CLEIO”, -Valérie Léveillé, CEO/founder NexPlasmaGen.

 

ABOUT NEXPLASMAGEN

NexPlasmaGen is converging the emerging field of cold plasma biotechnology into personalized cancer treatment. We are developing high-precision cold plasma delivery systems with the capability to kill cancer cells while sparing surrounding healthy tissue. NexPlasmaGen’s first application is in the treatment of breast cancer. Its patented cold plasma medical device is used to improve patient outcomes in breast conserving therapy.

Contact:

Valérie Léveillé, CEO/Founder

1-514-229-9458, valerie.leveille@nexplasmagen.com, https://nexplasmagen.com/

 

ABOUT CORPORATE LIVEWIRE

Corporate LiveWire is brought to you by Fenice Media Ltd., a publishing house with an international presence. The company offers both printed and digital media offering news and insight to readers from around the world.

Contact:

Dilan Parbat, Corporate LiveWire

+44 (0) 121 638 0405

www.corporatelivewire.com

dilan@corporatelivewire.com

No Comments

Post A Comment